PROQR THERAPEUTICS NV (PRQR)

NL0010872495 - Common Stock

1.94  -0.02 (-1.02%)

After market: 1.98 +0.04 (+2.06%)

Fundamental Rating

3

Taking everything into account, PRQR scores 3 out of 10 in our fundamental rating. PRQR was compared to 588 industry peers in the Biotechnology industry. While PRQR seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, PRQR is valued expensive at the moment.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year PRQR has reported negative net income.
PRQR had a positive operating cash flow in the past year.
PRQR had negative earnings in each of the past 5 years.
PRQR had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

PRQR has a better Return On Assets (-20.39%) than 82.36% of its industry peers.
PRQR has a Return On Equity (-67.92%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -20.39%
ROE -67.92%
ROIC N/A
ROA(3y)-29.27%
ROA(5y)-36.61%
ROE(3y)-73.83%
ROE(5y)-72.59%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PRQR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

5

2. Health

2.1 Basic Checks

PRQR does not have a ROIC to compare to the WACC, probably because it is not profitable.
PRQR has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for PRQR has been increased compared to 5 years ago.
PRQR has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -3.08, we must say that PRQR is in the distress zone and has some risk of bankruptcy.
PRQR has a Altman-Z score (-3.08) which is comparable to the rest of the industry.
The Debt to FCF ratio of PRQR is 0.98, which is an excellent value as it means it would take PRQR, only 0.98 years of fcf income to pay off all of its debts.
PRQR has a Debt to FCF ratio of 0.98. This is amongst the best in the industry. PRQR outperforms 95.89% of its industry peers.
PRQR has a Debt/Equity ratio of 0.44. This is a healthy value indicating a solid balance between debt and equity.
PRQR has a worse Debt to Equity ratio (0.44) than 71.92% of its industry peers.
Although PRQR does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF 0.98
Altman-Z -3.08
ROIC/WACCN/A
WACC6.75%

2.3 Liquidity

PRQR has a Current Ratio of 3.54. This indicates that PRQR is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.54, PRQR is not doing good in the industry: 60.62% of the companies in the same industry are doing better.
A Quick Ratio of 3.54 indicates that PRQR has no problem at all paying its short term obligations.
PRQR has a Quick ratio of 3.54. This is comparable to the rest of the industry: PRQR outperforms 41.27% of its industry peers.
Industry RankSector Rank
Current Ratio 3.54
Quick Ratio 3.54

More info and screens

5

3. Growth

3.1 Past

PRQR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 61.54%, which is quite impressive.
Looking at the last year, PRQR shows a very strong growth in Revenue. The Revenue has grown by 113.57%.
The Revenue has been growing by 10.58% on average over the past years. This is quite good.
EPS 1Y (TTM)61.54%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q56.25%
Revenue 1Y (TTM)113.57%
Revenue growth 3Y0.26%
Revenue growth 5Y10.58%
Revenue growth Q2Q374.43%

3.2 Future

PRQR is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -15.53% yearly.
The Revenue is expected to grow by 16.68% on average over the next years. This is quite good.
EPS Next Y-18.66%
EPS Next 2Y-15.76%
EPS Next 3Y-15.53%
EPS Next 5YN/A
Revenue Next Year-14.39%
Revenue Next 2Y17.38%
Revenue Next 3Y-4.31%
Revenue Next 5Y16.68%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

PRQR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRQR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

PRQR's Price/Free Cash Flow ratio is rather cheap when compared to the industry. PRQR is cheaper than 98.97% of the companies in the same industry.
Industry RankSector Rank
P/FCF 7.3
EV/EBITDA N/A

4.3 Compensation for Growth

PRQR's earnings are expected to decrease with -15.53% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.76%
EPS Next 3Y-15.53%

More info and screens

0

5. Dividend

5.1 Amount

PRQR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROQR THERAPEUTICS NV

NASDAQ:PRQR (4/26/2024, 7:11:16 PM)

After market: 1.98 +0.04 (+2.06%)

1.94

-0.02 (-1.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap157.82M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -20.39%
ROE -67.92%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 3.54
Quick Ratio 3.54
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)61.54%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-18.66%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)113.57%
Revenue growth 3Y0.26%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y